203 related articles for article (PubMed ID: 29501085)
21. Anti-glutamic acid decarboxylase (GAD) positive cerebellar Ataxia with transitioning to progressive encephalomyelitis with rigidity and myoclonus (PERM), responsive to immunotherapy: A case report and review of literature.
Jazebi N; Rodrigo S; Gogia B; Shawagfeh A
J Neuroimmunol; 2019 Jul; 332():135-137. PubMed ID: 31015081
[TBL] [Abstract][Full Text] [Related]
22. Neurological Syndromes Associated with Anti-GAD Antibodies.
Dade M; Berzero G; Izquierdo C; Giry M; Benazra M; Delattre JY; Psimaras D; Alentorn A
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456344
[TBL] [Abstract][Full Text] [Related]
23. Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis.
Georgieva Z; Parton M
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24419643
[TBL] [Abstract][Full Text] [Related]
24. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients.
Honnorat J; Saiz A; Giometto B; Vincent A; Brieva L; de Andres C; Maestre J; Fabien N; Vighetto A; Casamitjana R; Thivolet C; Tavolato B; Antoine J; Trouillas P; Graus F
Arch Neurol; 2001 Feb; 58(2):225-30. PubMed ID: 11176960
[TBL] [Abstract][Full Text] [Related]
25. Opsoclonus in a patient with increased titers of anti-GAD antibody provides proof for the conductance-based model of saccadic oscillations.
Shaikh AG; Wilmot G
J Neurol Sci; 2016 Mar; 362():169-73. PubMed ID: 26944142
[TBL] [Abstract][Full Text] [Related]
26. Centripetal Nystagmus, Slow Saccades, Cerebellar Ataxia, and Parkinsonism in a Patient With Anti-GAD65-Associated Stiff Person Syndrome Spectrum Disorder.
Hac NEF; Murphy OC; Butala AA; Newsome SD; Gold DR
J Neuroophthalmol; 2023 Jun; 43(2):273-276. PubMed ID: 36728609
[TBL] [Abstract][Full Text] [Related]
27. Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies.
Vianello M; Tavolato B; Armani M; Giometto B
Cerebellum; 2003; 2(1):77-9. PubMed ID: 12882238
[TBL] [Abstract][Full Text] [Related]
28. Clinical Characteristics and Management of 50 Patients with Anti-GAD Ataxia: Gluten-Free Diet Has a Major Impact.
Hadjivassiliou M; Sarrigiannis PG; Shanmugarajah PD; Sanders DS; Grünewald RA; Zis P; Hoggard N
Cerebellum; 2021 Apr; 20(2):179-185. PubMed ID: 33084997
[TBL] [Abstract][Full Text] [Related]
29. Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders.
Pearce DA; Atkinson M; Tagle DA
Neurology; 2004 Dec; 63(11):2001-5. PubMed ID: 15596740
[TBL] [Abstract][Full Text] [Related]
30. Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder.
Macaron G; Willis MA; Ontaneda D; Fernandez H; Kim S; Jones SE; Pioro EP; Cohen JA
Neurology; 2020 Feb; 94(6):273-275. PubMed ID: 31892635
[No Abstract] [Full Text] [Related]
31. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Abele M; Weller M; Mescheriakov S; Bürk K; Dichgans J; Klockgether T
Neurology; 1999 Mar; 52(4):857-9. PubMed ID: 10078741
[TBL] [Abstract][Full Text] [Related]
32. Downbeating nystagmus and muscle spasms in a patient with glutamic-acid decarboxylase antibodies.
Ances BM; Dalmau JO; Tsai J; Hasbani MJ; Galetta SL
Am J Ophthalmol; 2005 Jul; 140(1):142-4. PubMed ID: 16038662
[TBL] [Abstract][Full Text] [Related]
33. GABA-A receptor impairment in cerebellar ataxia with anti-glutamic acid decarboxylase antibodies.
Hosoi Y; Suzuki-Sakao M; Terada T; Konishi T; Ouchi Y; Miyajima H; Kono S
J Neurol; 2013 Dec; 260(12):3086-92. PubMed ID: 24091766
[TBL] [Abstract][Full Text] [Related]
34. Autoantibody-mediated disorders of the central nervous system.
Irani S; Lang B
Autoimmunity; 2008 Feb; 41(1):55-65. PubMed ID: 18176865
[TBL] [Abstract][Full Text] [Related]
35. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia.
Takenoshita H; Shizuka-Ikeda M; Mitoma H; Song S; Harigaya Y; Igeta Y; Yaguchi M; Ishida K; Shoji M; Tanaka M; Mizusawa H; Okamoto K
J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):386-9. PubMed ID: 11181864
[TBL] [Abstract][Full Text] [Related]
36. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus.
Kanter IC; Huttner HB; Staykov D; Biermann T; Struffert T; Kerling F; Hilz MJ; Schellinger PD; Schwab S; Bardutzky J
Epilepsia; 2008 May; 49(5):914-20. PubMed ID: 18177354
[TBL] [Abstract][Full Text] [Related]
37. Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
Jones AL; Flanagan EP; Pittock SJ; Mandrekar JN; Eggers SD; Ahlskog JE; McKeon A
JAMA Neurol; 2015 Nov; 72(11):1304-12. PubMed ID: 26414229
[TBL] [Abstract][Full Text] [Related]
38. Acute Cerebellar Ataxia Associated with Anti-glutamic Acid Decarboxylase Antibodies Mimicking Miller Fisher Syndrome.
Nakamura Y; Nakajima H; Hosokawa T; Yamane K; Ishida S; Kimura F
Intern Med; 2018 Jan; 57(2):269-271. PubMed ID: 29093402
[TBL] [Abstract][Full Text] [Related]
39. [Autoantibodies to GAD and autoimmune-mediated neurological diseases].
Mitoma H; Mizusawa H
Nihon Rinsho; 2013 May; 71(5):921-6. PubMed ID: 23777105
[TBL] [Abstract][Full Text] [Related]
40. Glutamic acid decarboxylase autoantibodies and neurological disorders.
Vianello M; Tavolato B; Giometto B
Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
